What is Ciprofloxacin
Ciprofloxacin is a broad-spectrum fluoroquinolone antibacterial agent that works by inhibiting bacterial DNA gyrase, an enzyme essential for bacterial DNA synthesis and replication. 1, 2
Mechanism of Action and Antimicrobial Spectrum
Ciprofloxacin exerts its bactericidal effect primarily through inhibition of DNA gyrase, which prevents bacterial DNA replication and leads to cell death. 1, 2 Unlike many other quinolones, ciprofloxacin may have multiple lethal effects on bacteria that are not completely reversible by inhibitors of protein or RNA synthesis. 2
Antimicrobial Coverage
Gram-negative bacteria: Ciprofloxacin demonstrates excellent activity against most Enterobacteriaceae (including E. coli, Citrobacter, Enterobacter, Serratia), Haemophilus influenzae, Neisseria gonorrhoeae, and Pseudomonas aeruginosa (MIC90 approximately 0.5 mcg/mL). 3, 1, 2
Gram-positive bacteria: Moderate activity against staphylococci, including methicillin-resistant Staphylococcus aureus, but streptococci (including Streptococcus pneumoniae) are not highly susceptible. 4, 1, 2
Anaerobes: Generally resistant to ciprofloxacin. 2
Dosing for Uncomplicated UTI Caused by Susceptible Citrobacter koseri
For an adult with an uncomplicated UTI caused by ciprofloxacin-susceptible Citrobacter koseri, ciprofloxacin should NOT be used as first-line therapy; however, if other recommended agents cannot be used, the dose is 500 mg orally twice daily for 7 days. 3, 5
Critical Prescribing Considerations
Reserve ciprofloxacin as an alternative agent: Fluoroquinolones should only be used when other recommended UTI antimicrobials (nitrofurantoin, trimethoprim-sulfamethoxazole, fosfomycin) cannot be employed due to concerns about antimicrobial resistance and adverse effects. 5
Local resistance patterns matter: Empiric ciprofloxacin is appropriate only when local community prevalence of fluoroquinolone resistance is ≤10%. 3, 5
If resistance exceeds 10%: Administer an initial one-time intravenous dose of a long-acting parenteral agent (such as 1 g ceftriaxone or a consolidated 24-hour aminoglycoside dose) before starting oral ciprofloxacin. 3, 5
Specific Dosing Regimen
- Standard oral dose: 500 mg twice daily for 7 days 3, 5
- Alternative extended-release formulation: 1000 mg once daily for 7 days 3, 5
- Optional initial IV dose: 400 mg intravenously once before starting oral therapy 3, 5
Pharmacokinetics
- Bioavailability: Approximately 70% after oral administration 1
- Peak serum levels: 1.5-2.9 mcg/mL after a single 500 mg oral dose 1
- Distribution: Widely distributed in body fluids and tissues, with concentrations typically equaling or exceeding concurrent serum levels 4, 1
- Elimination: Renal excretion, metabolism, and biliary excretion; dosage reduction required in severe renal dysfunction 6
Common Pitfalls and Caveats
Resistance development: Resistance can emerge during treatment, particularly with Pseudomonas aeruginosa and Staphylococcus aureus. 6, 1
Not for streptococcal infections: Ciprofloxacin should not be considered first-line empirical therapy for respiratory tract infections where penicillin-susceptible Streptococcus pneumoniae is the primary pathogen. 7
Drug interactions: Clinically important drug interactions are well documented and avoidable with conscientious prescribing. 7
Renal dosing: Major dosage adjustments are not required until creatinine clearance is <30 mL/min/1.73m² or serum creatinine is ≥2 mg/dL. 7